BOSTON ( TheStreet) -- The Best Biotech CEO of 2011 Award is in your hands.
Readers of TheStreet's biotechnology coverage will vote for the chief executive officer who exemplifies outstanding leadership and performance this year.
The five nominees for Best Biotech CEO of 2011 honors are Schaefer Price of Pharmasset (VRUS), Spectrum Pharma's (SPPI) Raj Shrotriya, Matt Emmens of Vertex Pharma (VRTX), David Hung of Medivation (MDVN) and Biogen Idec's (BIIB) George Scangos.
One of these executives will win the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO. Past winners include Dendreon's (DNDN) Mitch Gold (2010), Human Genome Sciences' (HGSI) Thomas Watkins (2009) and Myriad Genetics' (MYGN) Peter Meldrum (2008).Similar to the Worst Biotech CEO of 2011 Award, please read the following nominating summaries and make your selection in the interactive poll at the end of this story. Feel free to post comments if you believe a CEO deserving of acclaim was left out of the voting. I'll tally your votes and award the trophy in a week. Schaefer Price, Pharmasset Price was already a Best Biotech CEO nominee before he negotiated the $11 billion acquisition of his company by Gilead Sciences (GILD). The jaw-dropping valuation for Pharmasset, a company without meaningful revenue and with hepatitis C drugs still in clinical trials cemented Price's spot on the list.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV